KAKEN PHARMACEUTICAL CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,520 JPY | +1.06% |
|
+1.21% | +4.92% |
ETFs positioned on Kaken Pharmaceutical Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.38% | 0 M€ | +11.43% | ||
| 0.03% | 0 M€ | +16.03% | ||
| 0.03% | 0 M€ | +16.31% | ||
| 0.03% | 0 M€ | +15.35% | - | |
| 0.02% | 0 M€ | +15.51% | - | |
| 0.02% | 0 M€ | +16.43% | ||
| 0.02% | 0 M€ | +16.52% | - | |
| 0.02% | 0 M€ | -.--% | - | |
| 0.01% | 0 M€ | +4.81% | - | |
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 0 M€ | +7.24% | - | |
| 0.00% | 0 M€ | +8.70% | - | |
| 0.00% | 0 M€ | +7.95% | - | |
| 0.00% | 0 M€ | +5.63% | - | |
| 0.00% | 0 M€ | +5.79% | - | |
| 0.00% | 0 M€ | +3.63% | - |
KAKEN PHARMACEUTICAL CO., LTD. is a Japan-based company engaged in the production and sale of pharmaceutical products. The Company operates in two business segments. The Pharmaceutical segment involves in the manufacture and sale of pharmaceuticals, medical devices and agricultural drugs. The Real Estate segment is engaged in the leasing of real estate.
Sector
Pharmaceuticals
Calendar
01/08/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
3,520
JPY
Average target price
3,500
JPY
Spread / Average Target
-0.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.92% | 855M | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- 4521 Stock
- Funds and ETFs Kaken Pharmaceutical Co., Ltd.